Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Chinese Journal of Cardiology ; (12): 890-894, 2006.
Article in Chinese | WPRIM | ID: wpr-238496

ABSTRACT

<p><b>OBJECTIVE</b>To evaluate whether lipid-lowering therapy with Xuezhikang can reduce the risk of cardiac events and total mortality in coronary heart disease (CHD) patients with or without hypertension.</p><p><b>METHODS</b>In this random, double-blinded, placebo controlled clinical trial, 2704 patients with hypertension and 2166 patients without hypertension were enrolled and capsule Xuezhikang 0.6 g Bid or placebo on the top of conventional therapy without other lipid-lowering drugs. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and total mortality.</p><p><b>RESULTS</b>Compared to placebo group, the incidence of cardiac events was reduced by 44.0% (P<0.0001) and 47.4% (P<0.0001) respectively in CHD patients with or without hypertension, and the total mortality was lowered by 35.8% (P=0.0012) and 28.6% (P=0.0737) respectively in CHD patients with or without hypertension. There was no significant difference in side effects between study groups.</p><p><b>CONCLUSION</b>Xuezhikang can reduce the cardiac events and mortality in CHD patients with or without hypertension.</p>


Subject(s)
Adolescent , Adult , Aged , Humans , Middle Aged , Coronary Disease , Drug Therapy , Mortality , Double-Blind Method , Drugs, Chinese Herbal , Therapeutic Uses , Hypertension , Drug Therapy , Mortality , Hypolipidemic Agents , Therapeutic Uses , Lipids , Blood , Phytotherapy , Survival Rate
2.
Chinese Journal of Cardiology ; (12): 1067-1070, 2005.
Article in Chinese | WPRIM | ID: wpr-253011

ABSTRACT

<p><b>OBJECTIVE</b>To elucidate whether lipid-lowering therapy with Xuezhikang can induce a decrease of cardiac events and an attenuation of total mortality in coronary heart disease (CHD) patients with diabetes.</p><p><b>METHODS</b>We designed a random, double-blinded, placebo controlled clinical trial in selected 591 patients. All patients were administrated with capsule Xuezhikang (0.6 g, Bid) or placebo in addition to conventional therapy. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and death from CHD.</p><p><b>RESULTS</b>(1) The incidence of CHD events and that of death from CHD were reduced by 50.8% (P = 0.0008) and by 44.1% (P = 0.0246) in treatment group, respectively; Also, the incidence of nonfatal myocardial infarction was reduced by 63.8% (P = 0.0151). (2) The incidence of stroke, tumor, and PCI/CABG were decreased by 20.2%. (3) The total mortality were lowered by 44.1% in treatment group (P = 0.0097).</p><p><b>CONCLUSION</b>Xuezhikang can effectively reduce the incidence of cardiac events and total mortality in CHD patients with diabetes.</p>


Subject(s)
Aged , Female , Humans , Male , Middle Aged , China , Coronary Disease , Drug Therapy , Diabetes Mellitus , Double-Blind Method , Drugs, Chinese Herbal , Therapeutic Uses , Follow-Up Studies , Hypolipidemic Agents , Therapeutic Uses , Secondary Prevention
SELECTION OF CITATIONS
SEARCH DETAIL